secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K/A
Filed at:   2026-05-12T12:56:29+00:00
Accession:  0001193125-26-218290
Event type: earnings
Sentiment:  negative
Materiality: 0.95
Item codes: 2.02, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma Q1 net loss $6.7M; setrusumab Phase 3 fails primary endpoint, regulator engagement begun
--------------------------------------------------------------------------------

- Net loss of $6.7M in Q1 2026 vs $12.9M in Q1 2025; cash and equivalents $36.2M as of March 31, 2026.
- Setrusumab Phase 3 studies in OI did not meet primary fracture-rate endpoints; high significance on BMD, vertebral fracture reduction, and PROs.
- Mereo and partner Ultragenyx initiated regulatory discussions for pediatric OI path; no approved therapies exist.
- Alvelestat partnership discussions active; single Phase 3 trial of ~220 patients with SGRQ (US) and lung density (EU) endpoints planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526218290/0001193125-26-218290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526218290/mreo-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer